Introduction {#S0001}
============

Prognostic significance of preoperative inflammatory biomarkers and traditional clinical parameters in patients with spinal metastasis from clear cell renal cell carcinoma: a retrospective study of 95 patients in a single center.

Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma (RCC), accounting for approximately 70% of all RCC cases.[@CIT0001]--[@CIT0003] Nearly 20--30% patients of CCRCC presented bone metastasis at the time of diagnosis, while 20% patients with localized CCRCC finally progressed into metastatic CCRCC, with the spine common site.[@CIT0004],[@CIT0005] Spinal metastasis causes malignant spinal cord compression (MSCC), defined as compression of the spinal cord or cord equina by metastatic or direct spread to the vertebrae that may cause neurological disability.[@CIT0006] MSCC exhibits paralysis, intractable pain, spinal instability, and hypercalcemia, increased morbidity and decreased quality of life of the patients.[@CIT0007],[@CIT0008] In our previous study,[@CIT0009] we reported surgical intervention and survival outcomes of 30 patients with spinal metastasis from CCRCC, in which the statistical results revealed that Tokuhashi score was the only independent prognostic indicator.[@CIT0009] However, the outcome obtained from that study is not convincing enough due to the small sample size. In addition, clinical practices have demonstrated that the conventional prognostic factors including sex, treatment history, surgical modality and Tomita score lack accuracy and adequacy in predicting the prognosis; therefore, more accessible and reliable prognostic indicators need to be explored to identify high-risk patients and allocate personalized treatment for the sake of improving the therapeutic and clinical outcome.

Increasing evidence has demonstrated that inflammatory mediators and cytokines produced by tumor inflammatory cells in the tumor microenvironment are important factors contributing to cancer progression by promoting proliferation, angiogenesis, and metastasis, reducing response to hormones and chemotherapeutic agents, and subverting adaptive immunity.[@CIT0010]--[@CIT0014] Targeting of inﬂammatory pathways has been indicated as a novel way to further enhance the therapeutic efficacy.[@CIT0015],[@CIT0016] Therefore, preoperative inflammatory biomarkers may be potential prognostic factors for patients with spinal metastasis from CCRCC. Accordingly, serum white blood cells, neutrophils, lymphocytes, platelets and acute-phase proteins, such as C-reactive (CRP) protein and albumin (ALB), have been evaluated in different tumors and found to predict the prognosis and response to treatment.[@CIT0017],[@CIT0018] The appearance of Circulating tumor cells (CTCs) in the peripheral blood indicated active disease, proliferation, and metastatic potency, and is followed by genomic analyses that provide data in terms of the tumor biology and real-time monitoring of the therapeutic efficacy.[@CIT0019] Given the association between inflammatory response and tumor progression, the prognostic significance of several preoperative inflammatory biomarkers has been suggested, including the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), ALB/globulin ratio (AGR), and CRP/ALB ratio (CAR). However, to the best of our knowledge, no publications in the medical literature have taken inflammatory factors as prognostic predictors of patients with spinal metastasis from CCRCC.

The aim of the present retrospective study was to evaluate the prognostic significance of several preoperative inflammatory biomarkers including the NLR, PLR, LMR, AGR, and CAR by comparing them with the conventional prognostic factors.

Materials and Methods {#S0002}
=====================

Patients {#S0002-S2001}
--------

Medical records of 157 patients with spinal metastasis from CCRCC who received surgical treatment in our tumor center between August 2005 and September 2016 were analyzed retrospectively. This research project was examined and approved by the medical ethics committee of Changzheng hospital before commencing this study, and written informed consent was obtained from all patients or their legal guardians. The study was in compliance with the Declaration of Helsinki.

The inclusion criteria were as follows: 1) spinal metastasis from CCRCC confirmed by clinical manifestations, radiological presentations, and postoperative pathology; 2) patients who underwent surgical treatment in our tumor center; 3) patients had not taken anti-inﬂammatory medicines or received immunosuppressive therapy including recent steroid exposure, or with chronic inﬂammatory diseases including autoimmune diseases and infections before operation; 4) patients without receiving preoperative adjuvant therapy; and 5) the laboratory test results obtained before surgery. Finally, 95 patients who met with these inclusion criteria were enrolled in this study, and the flow diagram is shown in [Figure 1](#F0001){ref-type="fig"}. The material of a typical case underwent total en bloc spondylectomy (TES) is shown in [Figure 2](#F0002){ref-type="fig"}.Figure 1Patient flow diagram.Figure 2A typical case underwent the removal of tumor by total en bloc spondylectomy in our center and was diagnosed as spinal metastasis from CCRCC. (**A**) Preoperative X-rays of anteroposterior and lateral spine demonstrated wedge deformation and osseous destruction in ninth thoracic spine. (**B**) Preoperative magnetic resonance imaging (MRI) indicated that the lesion showed low-intensity signal on T1-weighted image and high-intensity signal on T2-weighted image. (**C**) Preoperative CT showed osteolytic destruction in first lumbar vertebrae and its posterior elements, paravertebral soft tissue mass, and compression of spinal cord. (**D**) Total en bloc spondylectomy was conducted, and the ninth thoracic vertebral body was removed. The postoperative X-rays showed the ninth thoracic spine was removed and replaced by titanium mesh, with solid internal-fixation.**Abbreviation:** CT, computed tomography.

The clinical and operative notes, radiographic images, and pathological reports of all patients who received surgery in our department for RCC spinal metastases were reviewed retrospectively. The preoperative neurological status was evaluated according to the Frankel score.[@CIT0020] The spinal tumors were classified based on Tomita classification[@CIT0021] and Tokuhashi score.[@CIT0022] Only overall survival (OS) was considered as the endpoint in this study. Event times were defined as the interval from the date of surgery to death, or until September 2016 for living patients. All patients were followed up on an outpatient basis at 3, 6, and 12 months after surgical treatment, every 6 months for the second year, and then annually for life.

Statistical Method {#S0002-S2002}
------------------

X-tile 3.6.1 software 20 (Yale University, New Haven, CT, USA) was used to determine the optimal cut-off values for NLR, PLR, LMR, and CAR. Quantitative data are described by median (range), and qualitative data are described as counts and percentages. Statistical calculations were analyzed using SPSS version 19.0 (SPSS, Inc. Chicago, IL, USA). Univariate and multivariate analyses were used to identify the independent significant factors especially preoperative inflammatory biomarkers that could predict prognosis for OS. Log-rank tests were performed for univariate analysis, and Cox proportional hazards model was used for multivariate analysis. OS were calculated by the Kaplan--Meier method. Factors with P value ≤ 0.10 in univariate analysis were subjected to multivariate analysis. Factors with P values ≤ 0.05 in multivariate analysis were considered statistically significant.

Results {#S0003}
=======

Patients' Baseline Characteristics and Optimal Cutoff Values of Inflammatory Biomarkers {#S0003-S2001}
---------------------------------------------------------------------------------------

The characteristics of all patients are detailed in [Table 1](#T0001){ref-type="table"}. The population comprised 84 males and 11 females with a mean age of 54.2 years (median, 56 years; range, 16--75 years). The mean follow-up time was 48.8 months (median, 51 months; range, 6--132 months). Of the 95 included patients, 21 died during the postoperative follow-up period, with death rate of 22.1%. The mean duration from initial surgery to death was 17.9 months (median, 15 months; range, 6--45 months). Of these patients, 80 patients were admitted for primary spinal metastasis from CCRCC, and the remaining 15 patients underwent surgical treatment for recurrences.Table 1Univariate and Multivariate Analysis of Clinical and Inflammatory Indicators for Overall Survival of Patients with Spinal Metastasis from CCRCCVariablesOverall SurvivalUnivariate Analysis*P* valueMultivariate Analysis HR(95%)*P* valueAge, year0.331 \<4011(11.6%) ≥4084(88.4%)Gender0.277 Male84(88.4%) Female11(11.6%)Treatment history\<0.001\* Primary80(84.2%) Recurrent15(15.8%)Duration time, month \<673(76.8%)0.610 ≥622(23.2%)Visceral metastasis0.211 Yes19(20.0%) No76(80.0%)PS0.421 0--252(54.7%) 3--443(45.3%)PFS0.197 A--C35(36.8%) D--E60(63.2%)Location0.789 Cervical spine23(24.2%) Thoracic spine34(35.8%) Lumber spine31(32.6%) Sacral spine7(7.4%)Involved segment0.871 Monosegment51(53.7%) Multisegment44(46.3%)Tomita score0.713 III--V69(72.6%) VI--VIII26(27.4%)Tokuhashi score\<0.001\* 4--941(43.2%) 10--1254(56.8%)Preoperative embolism0.871 Yes44(46.3%) No51(53.7%)Surgical approach0.462 Anterior4(4.2%) Posterior77(91.6%) Combined4(4.2%)Resection mode\<0.001\* Subtotal12(12.6%)1.000 Piecemeal73(76.8%)0.319(0.119--0.859)0.024^☨^ En bloc10(10.6%)0.196(0.024--1.631)0.132Intraoperative chemotherapy0.292 Yes68(71.6%) No27(28.4%)Postoperative radiotherapy0.329 Yes16(16.8%) No79(83.2%)Postoperative chemotherapy0.612 Yes7(7.4%) No88(92.6%)Targeted therapy0.001\*0.016^☨^ Yes56(59.0%)1.000 No39(41.0%)3.471(1.260--9.563)Bisphosphonates0.327 Yes32(33.7%) No63(66.3%)Blood loss0.381 Yes49(51.6%) No46(48.4%)NLR\<0.001\*\<0.001^☨^ \<3.876(80.0%)1.000 ≥3.819(20.0%)8.332(2.74--24.938)PLR\<0.001\*0.010^☨^ \<206.981(85.3%)1.000 ≥206.914(14.7%)3.808(1.370--10.584)AGR0.566 \<1.541(43.2%) ≥ 1.554(56.8%)LMR0.310 \<2.351(53.7%) ≥2.344(46.3%)CAR0.230 \<1.232(33.7%) ≥1.263(66.3%)[^2][^3]

The optimal cut-off value of NLR, PLR, LMR, and CAR was determined by the X-tile program, which was 3.8, 206.9, 2.3, and 1.2, respectively ([Figure 3](#F0003){ref-type="fig"}). The log-rank value for NLR, PLR, LMR, and CAR was 63.5, 47.0, 51.0, and 8.2, respectively. According to the standard value reported by the Clinical Laboratory Department in Changzheng Hospital (Shanghai, China), the cut-off value for AGR was 1.5. Therefore, all patients were divided into two groups for further analysis (NLR\<3.8 and NLR≥3.8; PLR\<206.9 and PLR≥206.9; AGR\<1.5 and AGR≥1.5; LMR\<2.3 and LMR≥2.3; CAR\<1.2 and CAR≥1.2).Figure 3X-tile analysis of OS was performed using patients' data to determine the optimal cut-off values for D-dimer, NLR, PLR, LMR, and CAR. The sample of spinal metastatic CCRCC patients was equally divided into training and validation sets. X-tile plots of training sets are shown in the left panels, with plots of matched validation sets shown in the small inset. The optimal cut-off values highlighted by the black circles in left panels are shown in histograms of the entire cohort (middle panels), and Kaplan-Meier plots are displayed in right panels. *P* values were determined by using the cut-off values defined in training sets and applying them to validation sets. The optimal cut-off values for NLR, PLR, LMR, and CAR were 3.8, 206.9, 2.3, and 1.2, respectively. (**A**) NLR, (**B**) PLR, (**C**) LMR, and (**D**) CAR.

Univariate and Multivariate Analyses of Prognostic Factors for OS {#S0003-S2002}
-----------------------------------------------------------------

Twenty-one patients died during the follow-up period, thus the OS rate of patients with spinal metastasis from CCRCC was 77.9%, with a median OS of 57.6 months (range, 24--132 months). The results of univariate and multivariate analyses of possible prognostic factors are shown in [Table 1](#T0001){ref-type="table"}. Univariate analysis revealed that significant difference was obtained in patients with treatment history (P \< 0.001), Tokuhashi score (P \< 0.001), resection mode (P \< 0.001), targeted therapy (P = 0.001), NLR (P \< 0.001), and PLR (P \< 0.001).

All potential prognostic factors obtained by univariate analysis were extracted into Cox proportional hazard for multivariate analysis ([Table 1](#T0001){ref-type="table"}). Patients who underwent TPS had longer OS than those who received TES or subtotal resection (TPS \[HR, 0.319, P = 0.024\] versus TES \[HR, 0.196; P = 0.132\]). Targeted therapy significantly increased chance of OS (HR, 3.471; P = 0.016). Patients with preoperative NLR \< 3.8 had longer OS than those with preoperative NLR≥ 3.8 (HR, 8.332; P \< 0.001). Simultaneously, preoperative PLR value≥206.9 significantly suggested poorer OS for patients with spinal metastasis from CCRCC (HR, 3.808; P = 0.010). The Kaplan--Meier curves of OS for resection mode, targeted therapy, NLR, and PLR are presented in [Figure 4A](#F0004){ref-type="fig"}--[D](#F0004){ref-type="fig"}. Therefore, resection mode, targeted therapy, NLR, and PLR were independent prognostic factors for OS.Figure 4Kaplan--Meier curves of overall survival for (**A**) Resection mode, (**B**) Targeted therapy, (**C**) NLR, and (**D**) PLR.

Clinical Management of Patients with Recurrent Spinal Metastasis from CCRCC {#S0003-S2003}
---------------------------------------------------------------------------

Based on the clinical manifestations and radiological presentations, 15 patients who received curettage in other hospitals were identified as having local recurrence of spinal lesions and chosen to undergo a second operation in our spinal tumor center. The characteristics of these recurrent patients are detailed in [Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}. Interestingly, all patients were male with a mean age of 58.8 (43--68) years. The spinal lesions were classified by Tomita classification, and the condition of the patients was assessed by the Tokuhashi score. All spinal lesions were classified as Tomita IV-VI in accordance with Tomita classification. In three patients (Case \# 10--12) with Tokuhashi score \< 9, TPS or subtotal resection was performed TPS or subtotal resection under the robust request of patients or their guardians. Unfortunately, all of them died during the follow-up period. Case \# 2 with the lesion classified as Tomita IV only received TES, and Case \# 1 with the tumor evaluated as Tomita VI underwent TES and postoperative targeted therapy. All patients who received TES were alive during the follow-up period. TPS was performed in eight patients, three of whom (Case \# 8,10,12) died of tumor recurrence, progression, and metastasis within 2 years, respectively. One patient (case \# 10) dead 45 months after surgical treatment. Meanwhile, all patients (case \# 9,11,13--15) who received subtotal resection died of tumor progression and metastasis. Case \# 3 and Case \# 7 received repeated operations for tumor recurrences in our spinal tumor center. To better understand the outcomes of different surgical methods, we conducted the Kaplan-Meier survival curve and Log-rank test and the result showed p value = 0.045 ([Figure 5](#F0005){ref-type="fig"}).Table 2Clinical Management of Recurrent Patients with Spinal Metastasis from CCRCCNoAge (years)/GenderDS(M)VMPre F-SLCTomita Classification/Tokuhashi ScoreSurgical ApproachResection ModeAdjuvant TherapyOS (m)Last Status145/M1.5NoDL3VI/12PTESTT132Alive255/M0.3NoDL3IV/13PTESNone98Alive3\*59/M2NoDS1-2IV/11PPiecemealNone56Alive464/M10NoES1-2VI/10PPiecemealTT50Alive564/M10NoCT1-2VI/9PPiecemealRT49Alive668/M1NoCL1,3V/9PPiecemealTT46Alive7\*55/M24YesDT6-8VI/11PPiecemealRT+TT45Dead862/M8NoDT8V/10PPiecemealTT18Dead949/M3NoEL7-8V/9PSubtotalNone15Dead1060/M4NoBL4-S1IV/7PPiecemealNone18Dead1165/M2NoEC6V/7A+PSubtotalNone10Dead1243/M0.5NoCT8-10IV/8PPiecemealTT24Dead1364/M8NoBT9V/9PSubtotalNone6Dead1464/M0.2NoCC5V/9PSubtotalNone8Dead1565/M3NoDL1V/9PSubtotalNone17Dead[^4][^5] Table 3Treatment Protocols and Outcomes of Recurrent Spinal Metastasis from CCRCCTreatment ProtocolNLocal RecurrenceDeadn%n%SurgerySubtotal resection54805100Total piecemeal spondylectomy8337.5450Total en bloc spondylectomy20000 Figure 5Kaplan--Meier curves of overall survival of recurrent patients for resection mode.

Discussion {#S0004}
==========

To the best of our knowledge, this is the largest monocentric retrospective study regarding the prognostic significance of clinical factors and inflammatory biomarkers. About 30% CCRCC patients developed bone metastasis, especially in the spine.[@CIT0023]

With the advance in surgical treatment, targeted therapy, and precise radiotherapy, the OS of spinal metastasis from CCRCC has improved remarkably in recent years.[@CIT0024]--[@CIT0026]

In this research, clinical factors and inflammatory biomarkers were analyzed to identify convenient and reliable prognostic biomarkers for identifying high-risk patients and improve the clinical outcome of spinal metastasis from CCRCC. Simultaneously, we attempted to find out answers to the following questions: Which parameters have the prognostic value for predicting OS for spinal metastasis from CCRCC?Do the inﬂammatory factors affect disease progression and OS?Do the widely used adjuvant therapies, such as adjuvant radiotherapy, intraoperative local treatment, and targeted therapy have a therapeutic effect?

The results obtained from this study suggest that resection mode, targeted therapy, NLR and PLR are significantly correlated with OS. Total resection is superior to subtotal resection for OS of patients with spinal metastasis from CCRCC. However, statistical analysis revealed that TPS could prolong the OS of patients compared with TES. With the development of targeted agents that inhibit the vascular endothelial grow factor (VEGF) and the mammalian target of rapamycin (mTOR) signal transduction pathways (7, 8), patients administered with targeted therapy had longer OS than those without it. Our finding demonstrated that NLR and PLR versus other indicators had a discriminatory ability as novel and promising inflammatory biomarkers.

Surgical treatment is the standard treatment based on Tomita classification for spinal metastasis with respect to preserving neurological functionality, relieving pain and promising prolonged survival.[@CIT0027]--[@CIT0029] Petteys et al[@CIT0025] reported that resection and fixation provided pain relief and neurological stabilization in patients with spinal metastasis arising from RCC, and aggressive intervention was beneficial to younger patients. Tatsui et al[@CIT0006] also supported surgical treatment as aggressive intervention on the basis of identifying several factors influencing survival. Our former study suggested that surgical treatment was not the independent prognostic factor for patients with spinal metastasis from CCRCC, but the sample size of that study is small.[@CIT0009] In the present study, we for the first time demonstrated that TPS, rather than TES and subtotal resection, was the most beneficial surgical approach. As spinal metastatic lesions usually exhibit paraspinal extensions involving even the soft tissue, TES is not feasible. Extensive tumor resection may cause loss of stability of the spine, which was a major concern. This risk has been minimized by the anterior interbody fusion with or without instrumentation.[@CIT0030] Simultaneously, blood bleeding in the procedure of surgical treatment was high owing to rich blood supply in metastasis from RCC, which requires the surgeons to complete the operation as soon as possible. Subtotal resection produces tumor residuals, which is likely to cause local recurrence and tumor progression. In such a case, TPS seems the most suitable of the three surgical approaches.

Although chemotherapy and radiotherapy as adjuvant therapies have been applied to the treatment of spinal metastasis from CCRCC, the therapeutic outcome remains controversial.[@CIT0031] Tao et al[@CIT0032] reported that the combination of surgery with stereotactic body radiation therapy could offer patients with spinal metastatic a chance of durable tumor control with minimal toxicity. However, chemotherapy and postoperative radiotherapy are not significant prognostic factors for OS. With the understanding of molecular biology of RCC, several targeted agents inhibiting VEGF and mTOR signal transduction pathways such as Sunitinib, Sorafenib, Temsirolimus, and Pazopanib have been put into clinical practice.[@CIT0033]--[@CIT0036] Meanwhile, statistical results in our study revealed that targeted therapy significantly prolonged the OS of patients with spinal metastasis from CCRCC. Increasing clinical evidence has proven that targeted therapy can downsize the tumor size, control tumor progression, and improve OS, in view of Sunitinib and Sorafenib as the first-line or second-line treatment.[@CIT0037],[@CIT0038] Furthermore, surgery in combination with targeted therapy is useful for patients with spinal metastasis from CCRCC in that it provides a new therapeutic strategy for such patients.

In addition, our results suggested that NLR and PLR could serve as reliable and novel inflammatory prognostic biomarkers superior to other indicators for spinal metastasis from CCRCC. The relationship between chronic inflammation and RCC has been investigated, and it is increasingly recognized that systemic inflammatory response plays a crucial role in RCC development and progression.[@CIT0039],[@CIT0040] However, there is no published information regarding the prognostic significance of preoperative inflammatory indicators for spinal metastasis from CCRCC. Zhun et al[@CIT0041] reported that a high preoperative PLR was correlated with poor prognosis in RCC patients, and Hu et al[@CIT0042] demonstrated that pre-operative NLR could be considered as a potential prognostic biomarker in RCC patients who underwent surgical resection. Recent studies[@CIT0043]--[@CIT0045] have demonstrated that neutrophils interact with tumor cells via secretion of cytokines, thus promoting tumor development, lymphocytes mediate immunological destruction of cancer cells; and platelets serve as chemoattractants to promote migration of tumor cells. These inﬂammatory backgrounds at least theoretically support the use of several inﬂammatory biomarkers as prognostic indicators of spinal metastasis from CCRCC. Tokuhashi score and Tomita classification are known as the most popular prognostic scores for patients with spinal metastasis.[@CIT0021],[@CIT0022] In our previous study,[@CIT0009] we found that only the Tokuhashi score was an independent prognostic factor for patients with CCRCC. Pettey et al[@CIT0046] reported that Tokuhashi score could be used for selecting surgical patients with RCC spinal metastases, and maybe more relevant as compared with its effectiveness in patients with spinal metastases from other cancers. However, our results showed that the Tokuhashi score was not a suitable prognostic factor for OS. In our opinion, targeted therapy may be able to prolong the survival of patients with a low Tokuhashi score. In recurrent cases, nine of the 15 recurrent patients in our series died during the follow-up period, suggesting that local recurrence maybe an adverse prognostic factor for OS. Our subtype analysis suggested that TES significantly prolonged the OS of recurrent patients.

The present study has some limitations. First, this is a retrospective single-center study. In addition, the follow-up duration is not long enough. Finally, the study only focused on the OS of patients who underwent surgical treatment.

Conclusion {#S0005}
==========

Our findings demonstrate that TPS and targeted therapy can significantly prolong the OS of patients with spinal metastasis from CCRCC. Besides, NLR and PLR are robust and convenient prognostic indicators whose discriminatory ability is superior to that of other preoperative inflammatory biomarkers. However, further multi-center studies are required to validate our results and conclusions.
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[^5]: **Abbreviations:** DS, duration of symptom; m, month; VM, visceral metastasis; pre F-S, preoperative Frankel score; LC, location; OS, overall survival; M, male; P, posterior; A, anterior; TES, total en bloc spondylectomy; CT, chemotherapy; TT, targeted therapy; RT, radiotherapy.
